Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer

被引：0
|
作者：
Fernandez Madrigal, Laura
Garcia Samblas, Victoria
Amor Urbano, Maria
Inoriza, Angel
机构：
[1] Hosp Juan Ramon Jimenez, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21153
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer
    Rusthoven, Chad G.
    Doebele, Robert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2814 - +
  • [32] ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
    Kim, Edward S.
    Barlesi, Fabrice
    Mok, Tony
    Ahn, Myung-Ju
    Shen, Junwu
    Zhang, Pingkuan
    Ou, Sai-Hong Ignatius
    FUTURE ONCOLOGY, 2021, 17 (14) : 1709 - 1719
  • [33] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [34] Primary resistance to ALK inhibitor in ALK-positive non-small-cell lung cancer.
    Kang, Jin
    Chen, Huajun
    Zhou, Qing
    Tu, Hai-Yan
    Zhang, Xu-Chao
    Jian, Su
    Wang, Zhen
    Wang, Bin-Chao
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer
    Richter, Johanna
    Dunst, Juergen
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (07) : 657 - 660
  • [36] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
  • [37] Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer
    Melosky, B.
    Cheema, P.
    Agulnik, J.
    Albadine, R.
    Bebb, D. G.
    Blais, N.
    Burkes, R.
    Butts, C.
    Card, P. B.
    Chan, A. M. Y.
    Hirsh, V.
    Ionescu, D. N.
    Juergens, R.
    Morzycki, W.
    Poonja, Z.
    Sangha, R.
    Tehfe, M.
    Tsao, M. S.
    Vincent, M.
    Xu, Z.
    Liu, G.
    CURRENT ONCOLOGY, 2018, 25 (05) : 317 - 328
  • [38] Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory
    Li, Yimeng
    Hao, Zhanpeng
    Ma, Yuyan
    Setiwalidi, Kaidiriye
    Zhang, Yingming
    Zhao, Yujia
    Fu, Xiao
    Liang, Xuan
    Ruan, Zhiping
    Tian, Tao
    Yao, Yu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) : 152 - 162
  • [39] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
    Kim, D. -W.
    Ahn, M. -J
    Shi, Y.
    De Pas, T. M.
    Yang, P. -C
    Riely, G. J.
    Crino, L.
    Evans, T. L.
    Liu, X.
    Han, J. -Y.
    Salgia, R.
    Lanzalone, S.
    Polli, A.
    Iyer, S.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
  • [40] Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
    Gadgeel, Shirish M.
    Shaw, Alice T.
    Govindan, Ramaswamy
    Gandhi, Leena
    Socinski, Mark A.
    Camidge, D. Ross
    De Petris, Luigi
    Kim, Dong-Wan
    Chiappori, Alberto
    Moro-Sibilot, Denis L.
    Duruisseaux, Michael
    Crino, Lucio
    De Pas, Tommaso
    Dansin, Eric
    Tessmer, Antje
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4079 - +
12345